Afya
A tollbooth on Brazilian medical education with room to compound
Afya is Brazil’s leading medical education platform with 3,768 approved medical school seats and a growing ecosystem spanning undergraduate programs, continuing medical education, and physician software.
Its core cash engine is the regulated, capacity‑constrained medical school network where cohorts pay for six years, yielding high visibility, strong margins, and robust cash conversion.
In 2025 Afya delivered R$3.70 billion in revenue and R$1.68 billion in adjusted EBITDA with 93.7% operating cash conversion; in 1Q26 revenue grew 8.2% year over year and adjusted EBITDA reached R$511 million at a 50.5% margin.
Net debt excluding IFRS 16 fell to R$1.15 billion by March 31, 2026, roughly 0.7 to 0.8 times adjusted EBITDA, and Afya holds a local AAA.br credit rating. The moat rests on regulatory barriers and efficient scale in underserved health regions, switching costs for in‑program students, and scale advantages in content, intake, and shared services.
Risks are real: Brazil’s Education Ministry (MEC) in February 2026 revoked its call for new private medicine courses, altering the growth backdrop; new supervisory actions link enforcement to the ENAMED medical exam where a Folha analysis highlighted weak scores at several Afya‑affiliated campuses.
Digital physician solutions show mixed traction with declining MAUs in 2025 and 1Q26. Currency and policy risks warrant a margin of safety, but the core seat base and cash generation make Afya resemble a long‑duration, capacity‑constrained “tollbooth.”.
Does Afya have a strong competitive moat?
Moat composition and weights: (1) Regulatory barriers and efficient scale (weight 35%): High.
Brazil’s MEC strictly allocates medical seats and supervises quality; Afya operates within capacity‑limited regions and amassed 3,768 approved seats, including incremental authorizations in Nov/Dec 2025 and Feb 2026. This creates durable, regionally efficient scale that deters new entrants. Score: 88. (2) Switching costs (weight 25%): High.
Students rarely transfer mid‑degree due to lost time/credits and entrance exam constraints across six‑year programs, supporting sticky cash flows. Score: 90. (3) Cost advantage and scale (weight 20%): Moderate‑high. Centralized content, intake, shared services, and post‑acquisition playbooks improve unit economics.
Score: 78. (4) Intangibles/brand (weight 10%): Mixed. Strong recognition in medical education, but public scrutiny of campus exam outcomes tempers the brand layer. Score: 60. (5) Network effects (weight 10%): Modest in digital (Whitebook/iClinic) with cross‑sell data loops yet recent MAU softness. Score: 55. Weighted outcome ≈ low‑80s.
Evidence set: seat count/guidance and cash metrics from FY25/1Q26 disclosures; MEC’s 2026 policy and ENAMED enforcement context.
Does Afya have pricing power in its industry?
Afya lifted its medical school net average ticket ex‑acquisitions by ~2.8% in 2025 to R$9,060 per month while maintaining very high occupancy across integrated schools, suggesting room for steady ticket compounding against a large demand/supply gap for physicians. Undergraduate scale plus select non‑medical programs broaden cross‑sell.
Constraints: (a) political optics and consumer sensitivity on tuition; (b) regulatory oversight tied to measured quality outcomes; and (c) digital segment requiring product‑led pricing (AI assistants, EMR automation) to offset MAU softness. Net: solid but not unconstrained pricing power, with more leverage in medicine seats than in software.
How predictable is Afya's business?
Predictability is anchored by multi‑year cohorts, seat maturation, and recurring academic calendars. FY25 revenue grew 11.9% with adjusted EBITDA up 15.4% and operating cash conversion at 93.7%. 1Q26 continued at an 8.2% revenue growth pace with a 50.5% adjusted EBITDA margin.
Growth beyond mid‑single digits depends on incremental seat approvals, campus ramps, and continuous intake execution. Digital MAU softness introduces a small variable layer, but it is a minority of revenue.
Geographic concentration in Brazil adds macro/FX exposure, but domestic demand for physicians and regulatory capacity constraints underpin steady long‑term volumes.
Is Afya financially strong?
Balance sheet is robust with net debt ex‑IFRS16 at R$1.15b as of March 31, 2026, down nearly R$373m year over year, supported by cash of R$1.33b. FY25 operating cash flow was R$1.53b; company‑reported FY25 free cash flow reached a record R$1.06b; 1Q26 operating cash conversion was 92.5%.
Net debt to adjusted EBITDA runs about 0.7–0.8x, and Moody’s Local Brazil upgraded Afya to AAA.br in April 2025. Debt is largely CDI‑linked; rate cycles matter, but liquidity and coverage are ample. Dividend capacity was demonstrated with a R$307m declaration on FY25.
How effective is Afya's capital allocation strategy?
Track record combines disciplined M&A for seats (e.g., UNIDOM in 2024, FUNIC in 2025) at attractive guided multiples, organic seat expansions, and internal reinvestment in content and digital tools. Afya repurchased shares in 1Q26 and returned cash via dividends (R$307m on FY25).
While acquisitions add execution risk and contingent payments, integration synergies and seat ramp histories are generally favorable. Capex of ~R$364m in 2025 supports growth rather than heavy maintenance. We note scrutiny of campus quality outcomes (ENAMED) increases the importance of reinvestment in academic quality.
Does Afya have high-quality management?
Afya is controlled via a dual‑class structure with Bertelsmann and the Esteves family holding effective control; governance is formalized and financial reporting is solid with audited 20‑F statements and effective ICFR. The team has executed on seat M&A and deleveraging while maintaining high cash conversion.
On the other hand, the public debate on ENAMED outcomes indicates execution gaps in parts of the academic network that management must address decisively. Board‑level oversight and recent committee leadership updates support maturing governance, but alignment is shaped by control dynamics.
Is Afya a quality company?
Afya is a good quality company with a quality score of 80/100
- Capacity‑constrained core: 3,768 approved seats with additional seat wins in late 2025 and Feb 2026; six‑year cohorts drive predictability and pricing discipline.
- Cash compounder: FY25 operating cash flow R$1.53b; company‑reported FY25 free cash flow R$1.06b; 1Q26 cash conversion 92.5%; net debt ex‑IFRS16 ~0.7–0.8x EBITDA and cash R$1.33b.
- Regulatory moat but quality scrutiny: MEC halted new-course call in Feb 2026 (less new competition) yet is enforcing ENAMED‑based supervision; Folha flagged multiple low‑scoring campuses.
- Digital optionality with execution risk: Whitebook/iClinic ecosystem adds cross‑sell potential, but MAUs slipped in 2025 and 1Q26, requiring product and AI feature upgrades.
- Owner‑minded governance and capital returns: controlling shareholder structure, AAA.br local rating, R$307m dividend declaration on FY25, and ongoing buybacks within a disciplined M&A playbook.
What is the fair value of Afya stock?
Is Afya a good investment at $14?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.